abstract |
The present invention relates to a pharmaceutical composition comprising a pharmacologically effective and stable human fibroblast growth factor 21 (FGF21) mutant, a pharmaceutical composition comprising an FGF21 mutant, and a method for treating such type 2 diabetes, obesity, dyslipidemia and / or metabolic syndrome . |